The trial will include patients with mesothelioma, melanoma, and small cell lung cancer. Credit: Nephron / commons.wikimedia.org.

Compass Therapeutics has announced the dosing of the first patient in a Phase Ib study of CTX-471 along with Merck’s (known as MSD outside the US and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for advanced solid tumours.

Compass, which is also the study sponsor, supplied CTX-471, and KEYTRUDA will be provided by Merck as part of a clinical partnership and supply agreement signed by the companies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase Ib trial will enrol metastatic or locally advanced non-small cell lung cancer patients.

It will also include patients with melanoma, mesothelioma, small cell lung cancer, and head and neck cancer that have progressed following treatment with a checkpoint inhibitor.

Study participants will receive the CTX-471 and KEYTRUDA combination with the aim of restoring response.

See Also:

Compass Therapeutics CEO and scientific founder Thomas Schuetz said: “We are very pleased to be making progress on our CTX-471 clinical programme with dosing of the first patient in the combination arm with KEYTRUDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited about the potential to build upon the responses observed with CTX-471 monotherapy across multiple tumour types and address significant unmet need in the field of cancer immunotherapy.”

The next generation, CD137 agonist, fully human, IgG4 antibody CTX-471 has an optimised affinity for an agonistic antibody.

It attaches to the CD137 receptor’s membrane proximal epitope, which will result in the improved activation of T-Cells and NK Cells.

In a Phase I dose escalation and cohort expansion study, CTX-471 demonstrated to be well-tolerated.

The Phase Ib monotherapy study is completely enrolled and underway. CTX-471 has been assessed in this trial in patients with advanced solid tumours who received a minimum of one checkpoint inhibitor post progression.